Cancer Science & Therapy

Stomach cancer is also called Gastric cancer. Gastric cancer is a type of cancer that appears in the lining of the stomach. It can be classified into various types of cancer, including gastric adenocarcinomas and lymphomas. Lymphomas and mesenchymal tumors can also develop in the stomach. Symptoms that can trigger these tumors include weight loss and vomiting. Early signs and symptoms of this condition include nausea, abdominal pain, blood in the stool and skin and eye yellowing among others.

The objective of this study is the assessment of the cytotoxic effect of a commercially available fermented soy beverage Haelan 951, which is a supplement widely used by cancer patients. The main ingredient of the product is soy that is rich in flavonoids, especially isoflavones. The formulation was tested for its efficacy as well as the determination of main ingredients with proliferation, viability, apoptosis assays and analytical techniques. Low concentrations of genistein and daidzein present in Haelan 951 were confirmed with HPLC, LC-MS and NMR. Cytotoxic effect against MCF7 cell line was observed with MTT, SRB and CVE at the maximum concentration (32%) after 48h of incubation. 8% Haelan 951 had apoptotic effect on all cancer cell lines tested. The formulation of the product could lead to false positive results as it was slightly soluble in all the solvents used and the viscosity was visually observed to be quite high.

Stomach cancer is also called as Gastric cancer. Gastric cancer is a type of cancer that appears in the lining of the stomach. It can be classified into various types of cancer, including gastric adenocarcinomas and lymphomas.

Breast cancer has ranked number one cancer among Indian females with age adjusted rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000 women in 2018. It is also the second leading cause of cancer death in women. Fortunately, with advances in detection and treatment, death rates from breast cancer are declining. More recent advancements in breast cancer therapy using novel mechanisms involving actionable cancer mutations and the body’s immune system have opened up new avenues for reducing the death rate further. Breast cancer is one cancer that, although not originally thought to be immunogenic, has had many encouraging results in the past few years. We aim to provide a succinct overview of breast cancer immunotherapy as well as possible future directions.